Geophysical Exploration of Vesta

Dawn’s year-long stay at Vesta allows comprehensive mapping of the shape, topography, geology, mineralogy, elemental abundances, and gravity field using it’s three instruments and highprecision spacecraft navigation. In the current Low Altitude Mapping Orbit (LAMO), tracking data is being acquired to develop a gravity field expected to be accurate to degree and order ~20 [1, 2]. Multi-angle imaging in the Survey and High Altitude Mapping Orbit (HAMO) has provided adequate stereo coverage to develop a shape model accurate to ~10 m at 100 m horizontal spatial resolution. Accurate mass determination combined with the shape yields a more precise value of bulk density, albeit with some uncertainty resulting from the unmeasured seasonally-dark north polar region. The shape and gravity of Vesta can be used to infer the interior density structure and investigate the nature of the crust, informing models for Vesta’s formation and evolution

Neutron Matter Distributions from Quasi-Elastic (p,n) Reactions

Supported by the National Science Foundation and Indiana Universit

Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma

Dramatic advances in the care of patients with advanced renal cell carcinoma have occurred over the last ten years, including insights into the molecular pathogenesis of this disease, that have now been translated into paradigm-changing therapeutic strategies. Elucidating the importance of signaling cascades related to angiogenesis is notable among these achievements. Pazopanib is a novel small molecule tyrosine kinase inhibitor that targets VEGFR-1, -2, and -3; PDGFR-α, PDGFR-β; and c-kit tyrosine kinases. This agent exhibits a distinct pharmacokinetic profile as well as toxicity profile compared to other agents in the class of VEGF signaling pathway inhibitors. This review will discuss the scientific rationale for the development of pazopanib, as well as preclinical and clinical trials that led to approval of pazopanib for patients with advanced renal cell carcinoma. The most recent information, including data from 2010 national meeting of the American Society of Clinical Oncology, and the design of ongoing Phase III trials, will be discussed. Finally, an algorithm utilizing Level I evidence for the treatment of patients with this disease will be proposed

Thermal radiation processes

We discuss the different physical processes that are important to understand the thermal X-ray emission and absorption spectra of the diffuse gas in clusters of galaxies and the warm-hot intergalactic medium. The ionisation balance, line and continuum emission and absorption properties are reviewed and several practical examples are given that illustrate the most important diagnostic features in the X-ray spectra.Comment: 37 pages, 16 figures, accepted for publication in Space Science Reviews, special issue "Clusters of galaxies: beyond the thermal view", Editor J.S. Kaastra, Chapter 9; work done by an international team at the International Space Science Institute (ISSI), Bern, organised by J.S. Kaastra, A.M. Bykov, S. Schindler & J.A.M. Bleeke

Study of a Depolarizing Resonance at the IUCF Cooler Ring

This research was sponsored by the National Science Foundation Grant NSF PHY-931478

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic annotation data along with multi-platform molecular profiles of more than 11,000 human tumors across 33 different cancer types. TCGA clinical data contain key features representing the democratized nature of the data collection process. To ensure proper use of this large clinical dataset associated with genomic features, we developed a standardized dataset named the TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR), which includes four major clinical outcome endpoints. In addition to detailing major challenges and statistical limitations encountered during the effort of integrating the acquired clinical data, we present a summary that includes endpoint usage recommendations for each cancer type. These TCGA-CDR findings appear to be consistent with cancer genomics studies independent of the TCGA effort and provide opportunities for investigating cancer biology using clinical correlates at an unprecedented scale. Analysis of clinicopathologic annotations for over 11,000 cancer patients in the TCGA program leads to the generation of TCGA Clinical Data Resource, which provides recommendations of clinical outcome endpoint usage for 33 cancer types